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Background-—Although advanced heart failure (HF) is a clinically documented risk factor for vascular cognitive impairment, the
occurrence and pathomechanisms of vascular cognitive impairment in early stages of HF are equivocal. Here, we characterize
vascular cognitive impairment in the early stages of HF development and assess whether cerebral hypoperfusion or prothrombotic
conditions are involved.
Methods and Results-—Tgaq*44 mice with slowly developing isolated HF triggered by cardiomyocyte-specific overexpression of
G-aq*44 protein were studied before the end-stage HF, at the ages of 3, 6, and 10 months: before left ventricle dysfunction; at the
stage of early left ventricle diastolic dysfunction (with preserved ejection fraction); and left ventricle diastolic/systolic dysfunction,
respectively. In 6- to 10-month-old but not in 3-month-old Tgaq*44 mice, behavioral and cognitive impairment was identified with
compromised blood-brain barrier permeability, most significantly in brain cortex, that was associated with myelin sheet loss and
changes in astrocytes and microglia. Brain endothelial cells displayed increased E-selectin immunoreactivity, which was
accompanied by increased amyloid-b1-42 accumulation in piriform cortex and increased cortical oxidative stress (8-OHdG
immunoreactivity). Resting cerebral blood flow measured by magnetic resonance imaging in vivo was preserved, but ex vivo
NO-dependent cortical arteriole flow regulation was impaired. Platelet hyperreactivity was present in 3- to 10-month-old Tgaq*44
mice, but it was not associated with increased platelet-dependent thrombogenicity.
Conclusions-—We report for the first time that vascular cognitive impairment is already present in the early stage of HF
development, even before left ventricle systolic dysfunction. The underlying pathomechanism, independent of brain hypoperfusion,
involves preceding platelet hyperreactivity and brain endothelium inflammatory activation. ( J Am Heart Assoc. 2018;7:e007694.
DOI: 10.1161/JAHA.117.007694.)
Key Words: blood-brain barrier • cognitive impairment • endothelium • heart failure • platelet
D isability related to cognitive impairment and dementia isrecognized as one of the greatest social and economic
challenges of the 21st century worldwide. It is estimated
that in 2010, over 35 million people lived with dementia,
and due to aging of the population, this number is
projected to grow to over 115 million in 2050.1 Alzheimer
disease is the most common form of dementia, the second
(>20% of cases) being represented by vascular dementia—
the most severe form of vascular cognitive impairment
(VCI). In the majority of older patients, VCI coexists with
and accelerates the onset of Alzheimer disease, and this
mixed vascular and neurodegenerative form of dementia
was recently identified as the primary cause of age-related
cognitive impairment.2,3
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Heart failure (HF) is one of the leading causes of morbidity
and mortality in developed countries.4 It is a progressive and
multifactorial condition leading to functional impairment of
ventricular diastolic and/or systolic function, which is differ-
entiated based on left ventricle (LV) ejection fraction (EF). In
the advanced stage around half of patients suffer from
diastolic failure—HF with preserved EF (HFpEF)—and the
remaining half suffers from systolic failure—HF with reduced
EF (HFrEF). Based on population studies, HF was recognized
as contributing to the development of cognitive impairment
and dementia.5-8
Clinical results show correlation between features of HF
and functional or structural brain pathology.5,9,10 The majority
of these findings relate to HFrEF patients with an advanced
stage of HF with insufficient systolic heart function. Based on
indirect evidence from clinical trials in which cognitive
function was improved after pharmacological compensation
of HF,11 improved adherence to treatment,12 and successful
cardiac resynchronization therapy13 or left ventricular assist
device implantation,14 2 major pathomechanisms of cognitive
impairment associated with HF were identified. These mech-
anisms are cerebral hypoperfusion and/or microemboli
originating from the left heart.15 Although there are reports
on development of cognitive impairment in preclinical stages
of HF8 as well as in HFpEF patients,6,16 underlying pathologies
are yet to be identified. Furthermore, pathomechanisms of
VCI at preclinical stages of HF and HFpEF seem to differ from
pathomechanisms of VCI at HFrEF. Indeed, the treatment
successful for HFrEF patients failed to demonstrate improve-
ment either in cognition or in HF progression in HFpEF
patients.17,18
Genetically modified animal models are optimal for study-
ing the role of isolated pathomechanisms in the development
of clinically heterogeneous diseases. In VCI studies, genetic
models of HF have not yet been implemented.19 So far,
experimental studies aimed at mimicking pathology present in
HFrEF patients (advanced systolic failure) have employed
mouse models in which HF or HF-pathology was induced
surgically or pharmacologically.19,20 Mice in these models
develop VCI pathology due to global brain hypoperfusion and
global reduction in cerebral blood flow (CBF). In turn, in
humans, before the development of advanced HF as well as in
HFpEF, global CBF remains unaltered in slowly progressing
heart deterioration.21,22
In this study we assessed (1) whether slowly progressing
heart pathology—before the development of LV systolic
dysfunction and end-stage HF—leads to VCI, and (2) what
roles the 2 previously proposed major cardiac pathomecha-
nisms—global cerebral hypoperfusion and prothrombotic
condition—play in VCI development. We employed Tgaq*44
mice in which HF develops due to slowly progressing
cardiomyopathy, which mimics human HF on a molecular,
morphological, phenotypic, and functional level.23-31 Their
pathology is triggered by postnatal activation of a cardiomy-
ocyte-specific transgene, causing agonist-independent, con-
stitutive activation of the Gaq pathway, present only in
cardiomyocytes.23,32 This genetic modification mimics con-
stant neurohormonal overstimulation of cardiomyocytes by
renin–angiotensin-aldosterone, sympathetic, and endothelin-
1–dependent systems, mediated by angiotensin AT1,
adrenergic a1, and endothelin ET-A receptor stimulation,
respectively.23-25
We ascertained that VCI occurs in the early stage of heart
pathology and before the development of systolic impairment
of LV function; hence, before the end-stage HF. Our results
suggest that, in Tgaq*44 mice at early stages of HF
development, a pathomechanism leading to brain endothelial
dysfunction and dysregulation of neurovascular coupling
occurs before the development of LV systolic dysfunction
and is not due to brain hypoperfusion or a prothrombotic state
but instead to brain endothelium pathology preceded by
platelet hyperreactivity. The brain endothelial dysfunction was
evidenced by inflammatory activation, blood-brain barrier
(BBB) permeability, oxidative stress, and b-amyloid cortical
Clinical Perspective
What Is New?
• Vascular cognitive impairment (VCI) occurs in the early
stage of heart pathology, before the development of systolic
impairment of left ventricle function.
• Underlying pathology of VCI at the early stage of heart
failure development is independent of pathomechanisms of
VCI identified in advanced heart failure such as brain
hypoperfusion or prothrombotic state.
• Underlying pathomechanisms of VCI in early heart pathol-
ogy involve preceding platelet hyperreactivity and subse-
quent brain endothelium inflammatory activation that result
in blood-brain barrier leakage, cortical oxidative stress, and
b-amyloid cortical accumulation as well as impairment of
endothelial NO-dependent regulation of vascular tone in
cortical arterioles.
What Are the Clinical Implications?
• VCI development at the preclinical stage of heart failure is
important in the clinical setting because it potentially
enables identification and early treatment of a large
population of patients at risk of VCI.
• The platelet hyperreactivity that precedes VCI symptoms
suggests a potential role of platelets in VCI treatment.
• Impairment of major brain endothelium functions (perme-
ability, blood flow regulation, inflammatory activation) in
heart failure–induced VCI appears to be critical for patients
with cognitive impairment of vascular origin.
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accumulation as well as impairment of endothelial NO-
dependent regulation of vascular tone in cortical arterioles.
Methods
The data, analytic methods, and study materials will be made
available on request to other researchers for purposes of
reproducing the results or replicating the procedure.
Animals
The animal protocol was reviewed and approved by the Local
Ethical Committee for Jagiellonian University; hence, all
experimental procedures were in accordance with institutional
guidelines. Tgaq*44 mice, generated and genotyped as
described previously,24 as well as wild-type control mice
(FVB) were bred at the Animal Laboratory of the Institute of
Experimental and Clinical Medicine of the Polish Academy of
Sciences in Warsaw. Mice were housed in pathogen-free
conditions, fed a standard laboratory diet, and given water
ad libitum. Due to a higher level of aggression in aging males
then females, which could influence behavior and cognitive
function, all experiments were performed on female Tgaq*44
and age-matched female FVB mice at the ages of 3, 6, and
10 months. Each experimental age group was studied on a
separate group of mice: 3-month FVB n=24, 6-month FVB
n=28, 10-month FVB n=50, 3-month Tgaq*44 n=25, 6-month
Tgaq*44 n=31, and 10-month Tgaq*44 n=51. In Tgaq*44
mice, systolic and diastolic heart function deteriorates over
time and becomes significantly impaired at the age of 14 to
16 months, which represents the end stage of HF in this
model.24-29 It is then characterized not only by severe
impairment of systolic and diastolic cardiac function but also
by impaired dobutamine reserve.30 Therefore, Tgaq*44 mice
at the ages of 3, 6, and 10 months represent relatively early
stages of HF development. At the age of 4 months, Tgaq*44
mice have preserved global cardiac function (EF=63%, cardiac
output [CO]=15 mL/min, preserved high-dose dobutamine
response) and show no functional difference from age-
matched control FVB mice; hence, younger-than-3-month
Tgaq*44 mice represent a functionally normal heart.28,29,31 At
the age of 6 months, Tgaq*44 mouse heart function param-
eters are lower (EF=59%, CO=14.4 mL/min, preserved high-
dose dobutamine response), but global cardiac function is still
fully maintained. Yet, at this stage we detect changes
characteristic for atrial pathology—lower atrial late flow
velocity and subtle diastolic dysfunction of LV—detectable
only as decreased myocardial radial strain but not as
hemodynamic parameter changes (EF/CO).29,31 At
10 months, global cardiac performance is decreased (ejection
rate, fraction area change).26,27,31 Therefore, Tgaq*44 mice at
the ages of 3, 6, and 10 months represent sequential stages
of heart failure development: normal heart, early diastolic, and
systolic/diastolic cardiac dysfunction, respectively. Further-
more, because there is significant deterioration of heart
function parameters from 6 to 14 months, but transition to
overt heart failure occurs in 8- to 12-month-old Tgaq*44 mice
(EF=54%, CO=13 mL/min, to EF=46%, CO=10 mL/min,
respectively) with the critical period between the ages of 10
and 12 months,33 we claim that Tgaq*44 mice at the age of
10 months still represent a relatively early stage of HF.31
Behavioral Tests
Behavioral tests were conducted between 9 AM and 2 PM in
constant white light. Before each test, all elements were
cleaned with alcohol to remove olfactory clues. Tests were
video recorded for subsequent analysis.
The open field test (OFT), adapted from Schiavone et al,34
was carried out in a circular arena (60 cm diameter) divided
into 6 equal fields. The test was conducted 1 day after
habituation (6 minutes in the arena). To perform the test,
animals were placed in the arena for 6 minutes, and a trained
and blinded observer counted the number of fields crossed,
which led to the test result.
The novel object recognition (NOR) test was adapted from
Giovannini et al.35 Animals were tested in a plastic box
(28940922 cm). On the first day (adaptation), animals were
allowed to explore the open field for 10 minutes. The next
day, animals were placed in the box (training) to familiarize
them with 2 identical objects for 10 minutes. After 60 min-
utes, animals were placed in the box again (choice trial). In the
choice trial, 1 of the familiar objects was replaced with a novel
object and animals were left to explore the box for
10 minutes. A trained, blinded observer measured the time
spent on exploration of each object (ie, touching, sniffing,
sitting in close proximity with nose directed to the object).
The NOR index was calculated using the following formula:
(NF)/(N+F) (where N=time spent on exploration of the novel
object during the choice trial; F=time spent on exploration of
the familiar object in the choice trial).35
Immunohistochemistry
Mice were anesthetized (100 mg/kg ketamine+10 mg/kg
xylazine IP) and transcardially perfused with 0.01 mol/L
phosphate-buffered saline (PBS) followed by 4% paraformalde-
hyde in PBS. The brains were removed, postfixed in
paraformaldehyde overnight, transferred to 30% sucrose in
0.01 PBS, and kept in a refrigerator for 3 to 5 days. The right
hemisphere of each brain was then frozen in 80°C, and
sections were cut at 40 lm in the coronal plane with a
freezing microtome. The left hemisphere of each brain was
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paraffin embedded, and sections were cut at 7 lm in the
coronal plane with a microtome for processing on a light/
fluorescence microscope.
Sections from frozen brain were blocked with NDS (normal
donkey serum). After the wash, sections were incubated in
0.1% Triton X-100 in PBS (PBST) for 15 minutes. Then, after
preincubation in NDS-buffer (5% NDS in PBST) for 1 hour, the
following antibodies (Ab) were added (all from Abcam,
Cambridge, UK): rabbit anti-BMP (1:1000), goat anti-Iba-1
(1:500), chicken anti-GFAP (1:800) for overnight incubation at
4°C. After washing cycles in PBST, sections were incubated
for 2 hours at room temperature with secondary antibodies
(Jackson ImmunoResearch, West Grove, PA): Cy3 to detect
BMP, 488 Dylight to detect Iba-1, and 647 Alexa Fluor to
detect GFAP, all at 1:400. After being washed in PBST,
sections were incubated in Hoechst blue/PBS (Invitrogen,
Carlsbad, CA) at a concentration of 20 lg/mL for 15 minutes
and rinsed in PBST. BMP/Iba-1/GFAP/Hoechst stain was
acquired with a scanning confocal microscope (Leica TCS SP
8, Wetzlar, Germany). For each mouse, 1 z-stack from 1 slide
stained with 4 dyes was collected for each of the studied
brain regions: prefrontal cortex (2.10 mm anterior to bregma),
anterior commissure (1.10 mm anterior to bregma), lateral
ventricle and striatum (0.02 mm anterior to bregma), corpus
callosum and cingulum (0.94 mm posterior to bregma), DG,
CA3, and CA1 (1.94 mm posterior to bregma). The z-stacks
were composed of 1-lm-thick optical sections for all regions
and were collected using a 920 oil objective on a Leica TCS
SP 8 confocal microscope using a 470- to 670-nm white light
laser, 488-nm argon laser, and 405-nm diode laser. The
pinhole, photomultiplier, and hybrid detectors’ gain and
contrast settings were kept constant for all image stacks
acquired from all animals.
Paraffinized 7-lm-thick sections from the region of primary
and secondary motor cortex as well as piriform cortex
(0.96 mm anterior to bregma) were automatically deparaf-
finized through graded alcohols, subjected to heat-induced
epitope retrieval for 15 minutes in 1:100 citrate buffer
(10 nmol/L, pH 6.0), and incubated for 1 hour at 4°C in
PBST buffer containing single antibodies raised against the
following: rabbit anti b-amyloid1-42 (BA 1-42; 1:50; Millipore,
Billerica, MA), rat anti E-selectin (CD62-E; 1:50, BD, Franklin
Lakes, NJ), and mouse anti 8-hydroxy-20-deoxyguanosine
(8-OHdG, 1:10, JaICA, Shizuoka, Japan). After washing cycles,
sections were incubated for 30 minutes at room temperature
with secondary and/or tertiary Ab: Cy3 to detect BA 1-42
(1:800, Jackson ImmunoResearch), first with streptavidin
(1:600) and then with Cy3 to detect CD62-E (1:800, Jackson
ImmunoResearch). 8-OHdG staining was visualized employing
DAB (3,30-diaminobenzidinetetrahydrochloride hydrate)
according to the manufacturer’s protocol, which involved
prestain blockage with 0.1% peroxide. BA 1-42 and CD62-E
stains were acquired using a 940 objective on an
AxioObserver.D1 inverted fluorescent microscope (Zeiss,
Oberkochen, Germany). 8-OHdG stain was acquired with an
automated Olympus BX51 light microscope with a 940
objective. The photomultiplier and contrast settings were kept
constant for all images acquired from all animals. ImageJ
(National Institutes of Health, Bethesda, MD) was used to
normalize and semiquantitatively analyze all images. The
GFAP, Iba-1, and MBP immunoreactivities in the selected
brain regions were analyzed as the percentage of area
occupied by the signal. Additionally, MBP immunoreactivity in
anterior commissure was analyzed as a texture pattern.
Detailed characteristics of antibodies can be found in
Table S1, region of interest (ROI) selection in Figures S1 and
S2 and analyses in Data S1.
In Vivo BBB Permeability
Anesthetized mice (100 mg/kg ketamine+10 mg/kg xyla-
zine, IP) were injected (femoral vein) with 4 mL/kg of a
solution comprising Evans Blue (EB, 70 kDa, Sigma Aldrich,
St. Louis, MO) and sodium fluorescein (NaF 0.45 kDa, Sigma
Aldrich) and saline (2% EB and 2% NaF in 0.9% saline). The dye
mixture was allowed to circulate for 10 minutes, before
simultaneous perfusion of left (systemic circulation) and right
ventricles (pulmonary circulation) with PBS for 15 minutes.
Lungs and brain were isolated. Cortex, hippocampus, cere-
bellum, and pons were further isolated from each brain.
Isolated brain structures and lungs were dry-weighed (for
result normalization) and homogenized in 200 lL of 50% TCA
(dissolved in distillated water). Homogenate was frozen and
kept at 20°C for subsequent dye concentration measure-
ments. Thawed homogenates were centrifuged (at 10625 g
for 12 minutes at 4°C), collected supernatant was diluted
with 1:3 volumes of 95% ethanol before photospectrometric
(Synergy 4, Bio-Tek, Winooski, VT) determination of EB
concentration (fluorescence: excitation at 590 nm, emission
at 645 nm; absorbance at 620 nm) and NaF concentration
(fluorescence: excitation at 460 nm, emission at 515 nm).
In Vivo CBF Imaging
CBF was measured using magnetic resonance imaging on a
9.4 T/21 cm (BioSpec 94/20 USR, Bruker, Ettlingen, Ger-
many) horizontal scanner equipped with a 39 mm diameter 1H
quadrature transmit/receive radio-frequency volume coil.
Animals were anesthetized with 2% isoflurane in a mixture
of air and oxygen delivered via a nose cone and injected IP
with 400 lL of saline to avoid dehydration. Throughout the
experiment lasting 1.5 hours, animals were in a prone
position, and their temperature was maintained at 37°C.
Electrocardiography, respiration, and temperature were
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monitored with the Monitoring and Gating System (SA Inc,
Stony Brook, NY).
Anatomical imaging was conducted with RARE (Rapid
Acquisition with Relaxation Enhancement) and short echo time
sequence before arterial spin labeling. The perfusion map was
placed in the same plane as the anatomical image for each
animal. RARE short echo time sequence parameters were
echo time (TE)=5 ms, repetition time (TR)=3508 ms, number
of averages (NA)=4, field of view (FOV)=20920 mm, matrix
size=1289128 pixels, rare factor=16, slice thickness=2 mm.
Arterial spin labeling imaging was conducted using the Flow-
Sensitive Alternative Inversion Recovery RARE pulse sequence
with the following parameters: TE=4.642 ms, TR=18 000 ms,
NA=6, FOV=20920 mm,matrix size=1289128, rare factor=72,
slice thickness=2 mm, selective inversion slice thickness=
4 mm, and 15 inversion recovery times from 30 to 8000 ms.
Fat suppression was used with a frequency-selective 90-degree
pulse. A 20920 mm field of view and 1289128 pixel image
matrix resulted in 0.1562590.15625 mm/pixel spatial resolu-
tion of perfusion images. The total arterial spin labeling
measurement time was 50 minutes.
Perfusion maps were created using ASL Perfusion Macro
software (ParaVision 5.1, Bruker, Ettlingen, Germany) and
further processed with ImageJ software (NIH, Bethesda, MD).
The threshold was applied to the perfusion maps to reject false
values (higher than 300 mL/min per 100 g or negative). As
ROI, cortex, hippocampus, and thalamus were chosen based on
anatomical images (Figure S3) acquired using RARE short echo
time sequence. CBF (mL/min per 100 g) for each ROI was
expressed as median value of analyzed ROI perfusion.
Endothelial Function in Isolated Intracerebral
Arterioles
Mice were euthanized by cervical dislocation. Subsequently,
isolation of intracerebral arterioles branching from the middle
cerebral artery was performed under a stereomicroscope
using Dumant forceps. The specimens were transferred in a
pipette to a thermostated chamber (Warner Instruments,
Hamden, CT) and mounted in a Luigs and Neumann perfusion
system (Ratigen, Germany). Vessels were aspirated into a
holding pipette (40-45 lm) and cannulated with a perfusion
pipette (20-22 lm). The driving pressure was increased until
the vessel opened and perfusion was established. The
perfusate consisted of PSS36 with 1% BSA in 5% CO2 in
atmospheric air and was driven from a reservoir pressurized
to 20 to 40 mm Hg. All experimental protocols started with a
30-minute period of equilibration after the perfusion had been
established (37°C), and during the equilibration vessels did
not develop myogenic tone. Viability was tested by adminis-
tration of a high KCl to the organ chamber (55 mmol/L),
containing 105 mol/L phentolamine. Cumulative concentration
response curves to U46619 (from 109 to 106 mol/L) were
performed on each vessel. The concentration of U46619 at
which the second highest contraction was observed was chosen
as the submaximal concentration. This resulted in a submaximal
concentration of U46619 between 107 and 106 mol/L. The
concentration of U46619 with the submaximum effect was
used to measure arteriole constriction with and without L-NAME
(Nx-nitro-L-arginine methyl ester) (10
4 mol/L). Furthermore,
effects of a single dose of sodium nitroprusside (SNP)
(105 mol/L) were tested on top of constriction to U46619
with and without L-NAME. Last, contraction to high potassium
was tested in the presence of L-NAME.
Systemic Platelet Reactivity
Platelet reactivity was assessed according to a previously
published protocol with modification.37 Briefly, subsequent to
anesthesia, blood was collected on heparin from the right
heart ventricle. Whole blood was diluted and either directly
processed according to a “wash blood” protocol38 or
incubated at 37°C for 60 minutes, with constant stirring in
a Xyzyk apparatus (Xyzyk Company, Krakow, Poland) and then
processed according to the “wash blood” protocol. Washed
blood, both stirred and unstirred, was incubated (30 minutes,
37°C) with ADP and with 2 Ab panels (Table S1): first, FITC-
conjugated anti-CD41/61 (platelets linage marker GpIIbIIIa)
and PE-conjugated anti-CD41/61 active form (platelet acti-
vation marker GpIIbIIIa active form) Ab and second, with FITC-
conjugated anti-CD41/61 and PE-conjugated anti-CD62P
(platelet activation marker P-selectin). Flow cytometry data
(2 000 000 events per sample) were collected on an LSRII
cytometer. The gating strategy, pictured in Figure S4, started
with platelet identification based on GpIIbIIIa expression and
forward scatter event size; then singlet platelets, selected
from the forward-scatter-H versus the forward-scatter-W
plots, were studied for GpIIbIIIa active form and P-selectin
surface expression. Results were expressed as the percentage
of platelets positive for activation marker and as median
fluorescent intensity of activation marker. Raw data were
compensated and analyzed using FlowJo software version 9.2
for Mac (Tree Star, San Carlos, CA). Abs were titrated to
achieve optimal resolution, and gates for GpIIbIIIa active form
and P-selectin were set using the “fluorescence minus one”
method.39
Ex Vivo Platelet-Dependent Thrombus Formation
Platelet thrombus formation under arterial flow conditions
was measured quantitatively ex vivo with a microchip-based
flow-chamber system T-TAS (Total Thrombus-formation Anal-
ysis System; Fujimori Kogyo Co Ltd, Tokyo, Japan). Subse-
quent to anesthesia (100 mg/kg ketamine+10 mg/kg
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xylazine, IP), whole blood was sampled via cardiac puncture,
immediately anticoagulated with hirudin (525 ATU hirudin/
mL blood), and left to rest for 1 hour. Platelet count was
measured in duplicate by a hematology analyzer (ABC Vet,
Horiba, Germany). Before the measurement, blood was gently
mixed, 300 lL was applied to T-TAS and perfused over a PL
microchip coated with collagen at a flow rate of 12 lL/min.
Development of thrombus was measured with 3 parameters:
time to onset of thrombus formation (time required to reach
the pressure of 10 kPa in the microcapillary; seconds),
occlusion time (time required to reach the pressure 60 kPa
in the microcapillary; seconds), and area under the flow-
pressure curve for 10 minutes after the start of the assay;
this parameter characterizes thrombus stability and
hence defines total thrombogenicity (PL12-AUC10, less than
60 kPa).40
Statistical Analysis
The data were analyzed using R version 3.3.1. The Shapiro test
was used to assess for the normality of the data. Two groups
with normally distributed data were compared using a 2-tailed
Student t-test; data from relative CBF and from arteriole
perfusion experiments were analyzed as paired (Paired Student
t-test). Two groups with nonnormally distributed data were
analyzed with a Mann-Whitney test. ANOVA and Tukey test
were used to perform multiple group comparisons. Box plots
were used to show data distribution (median, Q1, Q3,
interquartile range, and outliers). Probability values (P) of less
than 0.05 were considered statistically significant.
Results
Behavioral and Cognitive Impairment in the Early
Stage of HF Development
To address the possible role of early-stage HF in the
development of cognitive impairment, we employed OFT and
NOR tests to compare the cognitive function of Tgaq*44 mice
versus age-matched FVB control mice at 3, 6, and 10 months
(n=8 per each group). OFT measured locomotor and behav-
ioral activity, whereas NOR assessed complex cognition
independent of motor activity. In OFT, activity of Tgaq*44
mice at 6 and 10 months was reduced by 48.2% (P=0.002)
and 60.2% (P=0.002), respectively, compared to age-matched
controls (Figure 1A). The NOR index at 6 months was lower
by 62.2% (P=0.003) and at 10 months by 65.9% (P=0.04) in
Tgaq*44 mice compared to age-matched controls (Fig-
ure 1B). Importantly, there was no difference between
performance of 3-month-old Tgaq*44 mice and control mice
at all ages (FVB at 3, 6, and 10 months) in OFT (P=0.996) and
NOR (P=0.93) tests.
Changes in Brain Nervous Tissue Associated With
Cognitive Impairment in the Early Stage of HF
Development
Because brain nervous tissue plays a crucial role in cognitive
processes, we assessed whether structural changes in its
components, myelin and glia, correspond with identified
cognitive deficits.41 Brains of Tgaq*44 mice at the age of 6
and 10 months (n=6) and brains of age-matched FVB mice
(n=4) were multiply stained for DAPI (nucleus) and for IBA-1,
GFAP, and MBP proteins specific for microglia, astroglia, and
axonal myelin sheath, respectively. Analysis of gray matter
revealed that brains from 6-month-old Tgaq*44 mice had a
reduced area occupied by IBA-1–immunopositive signal
(microglia) by 70% in the prefrontal cortex (P=0.047) as
compared to FVB brains. In both groups of Tgaq*44 and FVB
mice, microglia had a rather similar ramified appearance.
Comparison of white matter structures between Tgaq*44 and
FVB mice at 6 and 10 months of age showed decreased area
occupied by fluorescence signal from microglia in both the
anterior commissure (by 44%, P=0.0006 and by 52%,
P=0.008, respectively, for age group) and the corpus callosum
(by 27%, P=0.047 and by 52%, P=0.007, respectively, for age
group). At the age of 6 months, Tgaq*44 versus FVB mice
had a 56% reduced area of GFAP immunoreactivity (astro-
cytes, P=0.006) in the anterior commissure and a 32%
reduced area occupied by MBP immunoreactivity (myelin
sheath, P=0.009) in the cingulum. Furthermore, the texture of
MBP-immunopositive fibers in the anterior commissure was
significantly different between Tgaq*44 and FVB brains at the
ages of 6 (P=0.001) and 10 months (P=0.02). The area
occupied by GFAP immunoreactivity of astrocytes adjoining
the lateral ventricle walls was reduced by 38% in 6-month-old
Tgaq*44 mice as compared to FVB mice, whereas in
10-month-old Tgaq*44 mice the percentage of GFAP
immunoreactivity was increased 2-fold compared to 6-
month-old Tgaq*44 mice (P=0.008) and showed a tendency
to be stronger compared to age-matched FVB mice (P=0.09).
Results are shown in Figure 2, Table, and Table S2.
Impairment of BBB in Early Stage of HF
Development
Selective permeability of the BBB is a critical function of the
neurovascular unit, which structurally depends on intracellular
tight junctions between brain microvascular endothelial cells.42
Dysfunction of the BBB is associated with development of
cognitive impairment and structural changes in neuroglia.2 In
vivo permeabilities of BBB and lung vessels were compared
between Tgaq*44 (n=7 per group) and FVBmice (n=6 per group)
at 3, 6, and 10 months of age. Tgaq*44 mice at 6 and
10 months of age had global impairment in BBB integrity as
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evidenced by increased BBB permeability in Tgaq*44 mice
compared to age-matched FVB controls in all studied brain
structures (cortex, hippocampus, pons, and cerebellum),
whereas lung vessel permeability was largely preserved (Fig-
ure 3, Figure S5). Similar to behavioral test results, BBB
permeability in Tgaq*44 mice at the age of 3 months was fully
preserved and comparable to the value in 3-month-old FVB
control mice. A pathological increase in BBB permeability in
Tgaq*44 mice was most significant in the cortex for both small
(NaF, 0.45 kDa) and large (EB, 70 kDa) permeability markers,
and it increased from 141% for NaF (P=0.006) and 150% for EB
(P=0.02) to 156% for NaF (P=0.002) and 171% for EB (P=0.002)
in 6- and 10-month-old Tgaq*44 mice, respectively, as
compared to age-matched FVB.
Progressive Cortical Brain Endothelial Cell
Inflammation in Early Stage of HF Development
Brain endothelial cells comprise the vascular element of BBB,
the dysfunction of which is caused by inflammation. Therefore,
we measured cortical vessel immunoreactivity to E-selectin,
which as a protein is expressed almost exclusively on
inflammatory activated endothelium.43 Frontal cortex sections
of brains from Tgaq*44 mice at the ages of 6 and 10 months
(n=4) and corresponding sections of age-matched FVB mice
(n=4) were stained for E-selectin (CD62-E). Analysis (pictured in
detail in Figure S2) was based on 14 cortical vessels identified
in slices from 10-month-old FVB mice and 9 cortical vessels
identified in each of the remaining groups (each section
represented 1 animal; an entire hemisphere cortex was
scanned for vessels with lumen diameters >20 lm). Tgaq*44
mice at the age of 6 months had over 2-fold higher (P=0.02)
and at the age of 10 months almost 6-fold higher (P<0.0001)
E-selectin immunoreactivity of the small cortical vessels
compared to age-matched FVB mice. Thus, there was a
progressive 2-fold increase in E-selectin expression from
6- to 10-month-old Tgaq*44 mice (P=0.02) (Figure 4A).
Increased Accumulation of b-Amyloid1-42 in
Piriform Cortex and Increased Cortical Oxidant
Stress in Early Stage of HF Development
To further verify whether brain vascular pathology is accompa-
nied by brain parenchymal degeneration, we assessed 2
common cortical markers of neurodegeneration, oxidative
stress and b-amyloid1-42 deposition,
2 in Tgaq*44 mice at the
ages of 6 and 10 months. Frontal cortex sections of Tgaq*44
mice and age-matched FVB mice were stained either for
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Figure 1. Development of behavioral and cognitive impairment in early stages of heart failure in Tgaq*44
mice. Tgaq*44 and FVB (wild-type control) mice at 3, 6, and 10 months of age (n=8) were studied with
(A) open field test and (B) novel object recognition (NOR) test. Data distribution is presented as box plots
(median, Q1, Q3, interquartile range, and outliers); *P<0.05; **P<0.005; horizontal dashed line represents
mean value for all FVB. Q1, Q3 indicate 25th and 75th percentiles, respectively.
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b-amyloid1-42 (n=4 per group) or 8-OHdG (FVB n=4 and
Tgaq*44 n=6). Figure 4B illustrates the accumulation of
pathologic b-amyloid1-42 in the piriform cortex of Tgaq*44
mice, which was 37-fold higher in 6-month-old Tgaq*44 mice
(P=0.01) and 21-fold higher in 10-month-old Tgaq*44 mice
(P=0.03) compared to age-matched FVBmice (measured as the
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Figure 2. Representative microphotographs of brain demonstrating changes in neuroglia and white matter in early stages of heart failure in
Tgaq*44 (n=6) as compared to FVB (n=4) mice. A, Decreased IBA-1 (microglia) immunoreactivity in prefrontal cortex in Tgaq*44 compared to
FVB (wild-type control) mice; (B) decreased MBP (myelin) immunoreactivity in cingulum (cg-dotted area) in Tgaq*44 compared to FVB mice;
(C) decreased IBA-1 immunoreactivity in anterior commissure (within dashed area) in Tgaq*44 compared to FVB mice and inserted
magnification of square area in upper right; (D) changes in myelin fiber texture in anterior commissure in Tgaq*44 compared to FVB mice and
inserted magnification of square area in upper right; (E) a decrease and an increase of GFAP (astrocyte) immunoreactivity in periventricular area
in 6- and 10-month-old Tgaq*44 mice, respectively, compared to FVB mice; scale bar for large microphotographs indicates 50 lm, for inserted
magnifications 25 lm; m, animal age in months; cg, cingulum; cc, corpus callosum.
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number of pixels with signal above background within each
ROI). Figure 4C illustrates an over 2-fold increase in oxidative
stress in Tgaq*44 mice compared to FVB mice at 6 (P=0.02)
and at 10 months of age (P=0.01) as well as a general age-
related increase in b-amyloid1-42 deposition from 6 to
10 months of age in both Tgaq*44 (P=0.01) and in FVB mice
(P=0.04).
Lack of Impairment of Resting CBF in Early Stage
of HF Development
Brain hypoperfusion is 1 of 2 major mechanisms underlying
development of cognitive impairment.44 Therefore, we com-
pared resting CBF in the cortex, hippocampus, and thalamus in
10-month-old Tgaq*44 (n=6) and FVB mice (n=7) (Figure 5A)
using in vivo magnetic resonance imaging. CBF was not
different between Tgaq*44 and FVB mice in the cortex (mean
flow 101.3 versus 105.4 mL/min per 100 g; 95% confidence
interval [CI] 27.1 to 35.4, respectively), hippocampus (mean
flow 124.7 versus 110.4 mL/min per 100 g; 95% CI 58 to
29.4, respectively), and thalamus (mean flow 136.2 versus
133.8 mL/min per 100 g; 95% CI44.7 to 39.9, respectively)
(Figure 5B). After pooling CBF results from Tgaq*44 and FVB
mice, the difference between absolute CBF in the thalamus
(mean flow 134.9 mL/min per 100 g) and cortex (mean flow
103.5 mL/min per 100 g) was borderline significant (P=0.07;
95% CI 2.88 to 65.73). To further assess whether blood was
distributed equally among the studied structures, the cortex
and hippocampus CBFs were expressed as relative to CBF in
the thalamus (ie, relative cortex CBF equals thalamus CBF
minus cortex CBF) in each animal. Relative CBF in the cortex
and in the hippocampus did not differ between Tgaq*44 and
FVB mice (Figure 5C). A comparison of relative CBF in
Tgaq*44 mice revealed significantly (P=0.02; 95% CI 42.9
to 3.9) lower CBF in the cortex (relative mean flow
34.9 mL/min per 100 g) compared to CBF in the hippocam-
pus (relative mean flow 11.5 mL/min per 100 g).
Impairment of NO-Dependent Regulation of
Vascular Tone in Isolated and Perfused Cortical
Arterioles in the Early Stage of HF Development
To assess whether HF pathology leads to local impairment
of brain arteriole autoregulation, which is often present in
advanced VCI,19,45 we assessed NO-dependent endothelial
function in isolated, perfused cerebral arterioles. Contrac-
tion of isolated brain arterioles (40-50 lm in diameter)
from Tgaq*44 (n=6) and FVB (n=7) mice at the age of
10 months was measured ex vivo in the isolated cannu-
lated arterioles. There was no significant difference between
cumulative vasoconstrictor response curves to thromboxane
A2 receptor agonist U46619 (Figure 6A). Arteriole contraction
Table. Microglia-, Astroglia-, and Myelin-Specific Protein Immunoreactivity in Selected Brain Regions in Tgaq*44 (n=6) and FVB
(n=6) Mice at 6 and 10 Months of Age
Prefrontal Cortex Dentate Gyrus Anterior Commissure Corpus Callosum Cingulum Lateral Ventricle
IBA-1 immunoreactivity for microglia, mean (SD)/median (IQR)*
FVB 6 m 4.7 (2.15) 1.27 (0.22) 5.76 (0.18) 2.09 (0.31)* 1.23 (0.33) N/A
Tgaq*44 6 m 1.41 (1.03)† 1.15 (0.49) 3.81 (0.7)† 1.67 (0.32)† 1.41 (0.26) N/A
FVB 10 m 3.49 (1.09) 1.19 (0.8) 5.62 (1.16) 2.62 (0.55) 1.83 (0.68) N/A
Tgaq*44 10 m 2.43 (1.23) 0.86 (0.36) 2.69 (0.71)‡ 1.26 (0.54)† 1.44 (0.32) N/A
GFAP immunoreactivity for astroglia, mean (SD)
FVB 6 m N/A 9.16 (2.81) 7.61 (1.62) 6.2 (2.09) 4.34 (1.3) 25.58 (9.09)
Tgaq*44 6 m N/A 7.49 (2.24) 3.35 (1.19)† 3.32 (2.03) 2.73 (1.35) 15.89 (4.21)†
FVB 10 m N/A 6.07 (3.24) 3.76 (1.9) 3.58 (0.57) 3.07 (1.09) 20.94 (7.46)
Tgaq*44 10 m N/A 8.1 (1.22) 4.18 (1.74) 3.7 (1.55) 3.31 (1.11) 31.39 (9.52)
MBP immunoreactivity for myelin, mean (SD)/median (IQR)*
FVB 6 m N/A N/A 0.19 (0.01)§ 45.83 (9.2) 56.7 (14.29)* N/A
Tgaq*44 6 m N/A N/A 0.12 (0.01)‡§ 42.33 (5.8) 40.43 (6.43)† N/A
FVB 10 m N/A N/A 0.1 (0.01)§ 41.76 (10.12) 40.67 (9.27) N/A
Tgaq*44 10 m N/A N/A 0.12 (0.01)†§ 50.64 (9.42) 32.81 (4.81) N/A
FVB indicates wild-type control mice; IQR, interquartile range; m, months; N/A, measurement not applicable/assessed.
*Refers to nonnormally distributed data and represents median and interquartile range (IQR).
P-value †<0.05, ‡<0.005.
Results represent percentage of signal-positive area, except for §texture analysis (IDM parameter).
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induced by U46619 was significantly increased in the
presence of L-NAME (a nonspecific NOS inhibitor) in FVB
mice only (mean difference 8.68%; P=0.03; 95% CI 1.3-16.05),
whereas Tgaq*44 mice were unresponsive to L-NAME
(mean difference 1.4%; P=0.75; 95% CI 12.1 to 9.3)
(Figure 6B). To assess whether NO-dependent pathology in
Tgaq*44 mice is caused by endothelial and/or vascular
muscle dysfunction, we tested vascular muscle response
to SNP (NO donor). After precontraction of arterioles with
U46619, a significant vascular muscle-dependent relax-
ation response to SNP in the presence of L-NAME was
recorded in both Tgaq*44 (mean difference 15.3%;
P=0.02; 95% CI 3.6-27.1) and FVB mice (mean difference
15.5%; P=0.03; 95% CI 1.7-29.2). Furthermore, arteriole
dilation was significantly greater in the presence than
in the absence of L-NAME for both Tgaq*44 (mean
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Figure 3. Development of changes in BBB permeability in early stages of heart failure in Tgaq*44 mice. Increase in relative (to age-matched
FVB mice) BBB permeability to (A) NaF and Evans Blue dyes in cortex of Tgaq*44 mice (n=7) at 6 and 10 months of age; and to (B) NaF in
cortex, hippocampus, pons, and cerebellum but not in lungs in Tgaq*44 mice (n=7) at 6 and 10 months of age. Data distribution is presented as
box plots (median, Q1, Q3, interquartile range, and outliers). Red dotted line indicates average permeability in FVB control mice (n=6); *P<0.05,
**P<0.005; BBB indicates blood-brain barrier; (a), based on absorbance; (f), based on fluorescence; Q1, Q3, 25th and 75th percentiles.
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difference 9.9%; P=0.004; 95% CI 4.7-15.1) and FVB mice
(mean difference 16.7%; P=0.01; 95% CI 5.2-28.1) (Fig-
ure 6C). An impaired effect of L-NAME on U46619-induced
vasoconstriction in Tgaq*44 mice was observed, but a
comparable response to SNP in Tgaq*44 and FVB mice
suggests an endothelial NO deficiency in Tgaq*44 mice.
On the other hand, there was no difference in arteriole
contraction and secondary dilation induced by high
potassium before and after addition of L-NAME (Fig-
ure S6).
Platelet Hyperreactivity in Early Stage of HF
Development
A prothrombotic state is 1 of 2 major mechanisms respon-
sible for VCI development in HF.44 Furthermore, platelet
activation, independent of preserved or reduced EF, is known
to be present in cardiomyopathy, and HF and was shown to be
linked to cardiac inflammation.46-48 Therefore, we measured
platelet responsiveness to stimulation in Tgaq*44 versus FVB
mice at the ages of 3, 6, and 10 months (n=10 per group) by
Figure 4. Endothelial inflammation of cortical vessel wall and related cortical pathology in early stage
heart failure in Tgaq*44 mice. A, Progressive increase in E-selectin immunoreactivity in cortical vessel
endothelial cells in 6- and 10-month-old Tgaq*44 (n=4) vs FVB (n=4) mice; representative images
illustrate E-selectin immunoreactivity in cortical vessel walls; (B) increased accumulation of b-amyloid1-42
in 6- and 10-month-old Tgaq*44 (n=4) vs FVB (n=4) mice in piriform cortex; representative images
(yellow) illustrate raw immunoreactivity of b-amyloid1-42 in piriform cortex, whereas overlapping images
represent quantitative measure (black dots in ROI, pointed by red arrow) of b-amyloid1-42 immuno-
reactivity; scale bar indicates 50 lm; (C) progressive increase in cortical oxidative stress in 6- and
10-month-old Tgaq*44 (n=6) vs FVB (n=4) mice at 6 and 10 months; representative raw images illustrate
8-OHdG signal intensity; scale bar indicates 100 lm; data distributions in (A) and (C) are presented as box
plots (median, Q1, Q3, interquartile range, and outliers); in (B) each result and group median is shown. Q1
and Q3 indicate 25th and 75th percentiles, respectively; ROI, region of interest; *P<0.05, **P<0.005.
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measuring surface expression of P-selectin and GpIIbIIIa after
2 types of stimulations (ADP and stirring). The first stimulation
with ADP (Figure 7A) induced an increase in frequency of
platelets expressing P-selectin in Tgaq*44 mice at 10 months
(P=0.001) and increased median fluorescence intensity,
representing level of platelet surface expression, of P-selectin
in 6- and 10-month-old Tgaq*44 mice (P=0.05, 0.0009,
respectively). The second stimulation, with stirring and ADP
(Figure 7B), further increased P-selectin expression in
Tgaq*44 mice. At 6 and 10 months, the increase in both
frequency of platelets expressing P-selectin (P=0.02, 0.002,
respectively) and platelets median fluorescence intensity of P-
selectin (P=0.009, 0.001, respectively) was identified in
Tgaq*44 mice compared to FVB mice. GpIIbIIIa platelet
expression after the first stimulation (Figure 7C) was
increased in Tgaq*44 mice in terms of frequency of platelets
expressing GpIIbIIIa at 3, 6, and 10 months (P=0.0002,
0.02, and 0.0004, respectively) as well as in terms of
platelet median fluorescence intensity of GpIIbIIIa at 3 and
10 months (P=0.01, 0.0004, respectively). The second
stimulation (stirring and ADP) (Figure 7D) did not induce
significant changes in GpIIbIIIa platelet expression in
Tgaq*44 or FVB mice.
Lack of Increased Platelet-Dependent
Thrombogenicity in the Early Stage of HF
Development
To further assess whether identified platelet hyperreactivity
induces a prothrombotic state, we compared platelet thrombus
formation between 10-month-old Tgaq*44 (n=8) and FVB mice
(n=8) in the microchip-based flow-chamber system T-TAS.
There was no significant difference (P=0.76; 95% CI 185 to
138) between platelet count in Tgaq*44 and control FVB mice
(Figure 8A). There was also no significant difference in platelet
thrombus formation between Tgaq*44 and FVB mice based on
all studied parameters: time to onset of thrombi formation
(P=0.8; 95% CI 29 to 37), occlusion time (P=0.79; 95% CI
46 to 59), and area under the flow pressure curve (P=0.43;
95% CI 45 to 20) (Figure 8B through 8D).
Discussion
This study, based on an experimental model, presents for the
first time the finding that VCI with vascular and brain
pathology is already present during the early stage of HF
development in normotensive Tgaq*44 mice, before LV
systolic dysfunction. Identification of hyperreactive platelets
before VCI development without detectable impairment of
resting CBF or severe prothrombotic state suggests a possible
inflammatory pathomechanism of VCI pathology in Tgaq*44
mice. Development of cognitive impairment appears to be
driven by dysfunction of the BBB due to progressive brain
endothelium inflammatory activation and is associated with
impairment of NO-dependent regulation of brain arteriolar
microcirculation.
HF—a common consequence of most heart diseases,
manifesting as structural or functional impairment of
ventricular filing and ejection of blood—is a recognized
independent risk factor for cognitive impairment and
dementia.49 Ventricular dysfunction in HF patients develops
due to various vascular risk factors: hypertension, diabetes
mellitus, coronary heart disease, obesity, or valvular heart
disease.4 These HF risk factors are also independent risk
factors for cognitive impairment.45 Concomitant presence of
vascular diseases made it difficult to identify and validate
Figure 4. Continued
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HF-specific pathology underlying cognitive impairment other
than that related to advanced functional hemodynamic heart
impairment. As indicated earlier, compensation of advanced
HF (HFrEF) does improve cognition. However, in the case of
the preclinical stage of HF, or HFpEF, in which heart function
is preserved, knowledge of mechanisms responsible for
cognitive impairment is significantly limited, and no treat-
ment is yet available.
Tgaq*44 mice are a unique model because cardiomyocyte
pathology leading to end-stage HF develops over a long
period of time (over 12 months), without the need for
surgical or therapeutic intervention. These interventions, in
other HF models, first cause heart decompensation (decom-
pensated HF) and subsequent heart remodeling that sec-
ondly lead to heart compensation (compensated HF)—a
baseline condition for experimental VCI studies.19 Therefore,
slowly progressing pathology in Tgaq*44 mice uniquely
enables the study of VCI development before development of
advanced, end-stage HF in the absence of preexisting
vascular risk factors. Pathological cardiac hypertrophy is
known to be caused by humoral activation, mechanical
stress, transcription switch to fetal gene program and is
linked to cardiac fibrosis.50,51 These changes are also
induced in Tgaq*44 mice via constitutive cardiomyocyte-
specific, postnatal activation of the Gaq pathway, which
mimics the effects of neurohormonal activation in cardio-
myocytes.23 Subsequently, at different time points, but
before development of end-stage HF, other signs of patho-
logical cardiac hypertrophy occur and progress. As early as
the fourth month, mRNA for the b-myosin heavy chain is
expressed in cardiomyocytes, indicating activation of fetal
genes24,26; cardiac fibrosis is already 4-fold higher compared
to control mice—indicating pathological tissue reorganization25
and increased compensatory expression of cardiomyocyte
desmin,25 subsequently resulting in extracellular matrix
remodeling and sarcomere pathological reorganization as in
mechanical stress.50 Altogether, cardiomyocyte pathology in
Tgaq*44 mice, while maintaining normotension,24 leads to
slowly progressing heart deterioration and HF that was
previously characterized,23,25–31 but it was not known
whether HF in this model results in VCI.
Evidence presented here suggests that VCI develops in
Tgaq*44 mice at the early stages of HF development and is
not due to brain hypoperfusion or the overt prothrombotic
state identified so far as the major pathomechanisms of HF-
induced VCI, but to brain endothelium pathology preceded by
platelet hyperreactivity. The brain endothelial dysfunction was
evidenced by inflammatory activation, BBB permeability,
oxidative stress, and b-amyloid cortical accumulation as well
as impairment of endothelial NO-dependent regulation of
vascular tone in cortical arterioles. Clinically, cardiomy-
opathies are known to cause platelet activation, a phe-
nomenon independent of left ventricular size, EF, or heart
function.46–48 Underlying mechanisms of this activation are
not yet fully understood, but platelet activation was shown to
correlate with myocardial inflammation.46 On the other hand,
thromboembolism is 1 of the 2 recognized mechanisms of
cognitive decline in advanced HF patients and occurs
commonly in patients with arrhythmia, causing micro and
macro brain infarcts, and both adherence to pharmacological
treatment and surgical cardiac resynchronization improve
patients’ cognition.4,12,13 In Tgaq*44 mice, development of
cardiomyopathy is associated with co-occurrence of
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A
B
C
50
10
0
15
0
20
0
25
0
hippocampus thalamus
C
B
F
 m
l/1
00
m
g/
m
in
C
B
F
 r
el
at
iv
e 
to
 th
al
am
ic
 C
B
F
 m
l/1
00
g/
m
in
−
60
−
40
−
20
0
10
cortex
cortex
hippocampus
*
FVB
Tgαq*44
FVB
Tgαq*44
Figure 5. Preserved CBF in early stages of HF in Tgaq*44 mice.
A, Representative cerebral blood perfusion maps of brains of
10-month-old Tgaq*44 and FVB mice; color bar represents blood
perfusion in mL/100 mg per minute. B, CBF in cortex, hippocam-
pus, and thalamus does not differ between Tgaq*44 (n=6) and
FVB (n=7) mice; (C) CBF in cortex and hippocampus expressed as
relative to thalamic CBF does not differ between Tgaq*44 (n=6)
and FVB (n=7) mice; relative cortical CBF is lower than relative
hippocampal CBF in Tgaq*44 mice; data distribution is presented
as box plots (median, Q1, Q3, interquartile range, and outliers);
dashed line indicates average thalamic CBF. CBF indicates
cerebral blood flow; HF, heart failure; Q1 and Q3 indicate 25th
and 75th percentiles, respectively; *P<0.05.
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numerous cardiomyocyte pathologies (fibrosis, fetal genes
expression, sarcomere pathology) associated with heart
inflammation51 and could be responsible for the chronic
activation of platelets that mechanistically contribute to
pathological cardiac remodeling as shown in other models.52
Interestingly, we found that platelets were hyperresponsive
(increased GpIIbIIIa expression), already at the age of
3 months before development of detectable BBB pathology
and cognitive deficits. A lack of significant differences in
platelet-dependent thrombogenicity in Tgaq*44 mice as
compared with FVB at 10 months of age, assessed ex vivo
in the microchip-based flow-chamber system T-TAS, suggests
that it is not the prothrombotic but rather the proinflamma-
tory role of platelets that may contribute to VCI. However,
T-TAS may not have the sensitivity to detect subtle alterations
in the prothrombotic phenotype of platelets; therefore
prothrombotic mechanisms cannot definitely be excluded.
Furthermore, as evidenced in atherosclerosis or diabetes
mellitus type 2, platelet-related proinflammatory mechanisms
frequently coexist with or lead to prothrombotic patho-
mechanisms.53,54
Altogether we suggest that platelet-dependent mecha-
nisms contribute to the activation of endothelial inflammation
(E-selectin brain vessel expression), to the impairment of brain
endothelial integrity and function (increased BBB permeabil-
ity), and to the impairment of NO regulation. Similarly, in type
2 diabetes mellitus, platelets are hypersensitive to agonists
and respond to subthreshold stimuli before development of
detectable vascular wall damage.53 Furthermore, GpIIbIIIa
receptor inhibition with tirofiban in diabetic patients under-
going percutaneous cardiac interventions resulted in
decreased inflammatory response.55 Experimental and clinical
results show that activated platelets interact via surface
molecules (ie, selectins) with circulating leukocytes and
endothelium, causing inflammation and vascular diseases
and contributing to disruption of endothelial barrier integ-
rity.56 In our model, BBB permeability was compromised in all
studied brain areas with the most significant permeability
-9 -8 -7 -6
70
80
90
100
Lu
m
in
al
di
am
et
er
(%
)
U46619
0
5
10
15
20
25
C
on
tr
ac
tio
n
(%
)
80
90
100
110
Lu
m
in
al
di
am
et
er
(%
)
- L-NAME
+ L-NAME
- L-NAME
+ L-NAME
U4661control 9 U46619
SNP 
U4661control 9 U46619
SNP 
80
90
100
110
Lu
m
in
al
di
am
et
er
(%
)
- L-NAME
+ L-NAME
FVB
FVB
FVB
Tgαq*44
Tgαq*44
Tgαq*44
*
**
BA
DC
Figure 6. Impairment of NO-dependent regulation of vascular tone in isolated perfused cerebral arterioles
in early stages of heart failure in 10-month-old Tgaq*44 as compared to FVB mice. A, Contraction response
curve to increasing U46619 concentration (from 109 to 105 mol/L); (B) effect of suboptimal U46619
dose on arteriole contraction with and without L-NAME; (C and D) the effect of SNP (105 mol/L) on
cortical arterioles before and after L-NAME in FVB (C) and Tgaq*44 mice (D); FVB mice n=7, Tgaq*44 mice
n=6; data distribution is presented as mean and SD. L-NAME indicates Nx-nitro-L-arginine methyl ester;
SNP, sodium nitroprusside. *P<0.05.
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Figure 7. Systemic inflammatory activation of platelets in early stages of heart failure in Tgaq*44
mice. Platelets response to 2-step activation first via ADP and second via ADP and 60 minutes of stirring
in FVB (n=10 per group) and Tgaq*44 (n=10 per group) mice at 3, 6, and 10 months of age. Level of
platelet activation is based on surface expression of either P-selectin (CD62p) or GpIIbIIIa, which are
measured as percentage of platelets expressing activation markers (marker-positive platelets) and level
of activation markers expression (marker MFI). A, Increased frequency of P-selectin–positive platelets
and increased P-selectin MFI expression after ADP stimulation in Tgaq*44 at 6 and 10 months. B,
Increased frequency of P-selectin–positive platelets and increased P-selectin MFI expression after
60 minutes mechanical and ADP stimulation in Tgaq*44 at 6 and 10 months. C, Increased frequency of
GpIIbIIIa-positive platelets and increased GpIIbIIIa MFI expression after ADP stimulation in 3-, 6-, and 10-
month-old Tgaq*44. D, GpIIbIIIa expression after ADP and 60 minutes of mechanical stimulation; data
distribution is presented as box plots (median, Q1, Q3, interquartile range, and outliers). *P<0.05,
**P<0.005, ***P<0.0005. 3m, 6m, and 10m indicate 3, 6, and 10 months, respectively; MFI, median
fluorescence intensity; Q1 and Q3 indicate 25th and 75th percentiles, respectively.
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increase in the brain cortex. Moreover, brain endothelial cells
—the vascular element of BBB—expressed an inflammatory
phenotype (E-selectins). Dysfunction of BBB and brain
endothelium is commonly found in postmortem brain tissues
of people suffering from cognitive impairment.57 In our study
cognitive impairment and increased BBB permeability were
both present by the age of 6 months, at which time Tgaq*44
mice display fully preserved systolic and global cardiac
function with early signs of diastolic dysfunction. Further-
more, cognitive impairment at 6 and 10 months was accom-
panied by reduced myelin signal and disarrangement of
myelinated fibers in major white-matter tracts (corpus callo-
sum, cingulum, anterior commissure). In parallel, we observed
changes in neuroglial protein immunoreactivity (astrocytes,
microglia) in cortex and above-mentioned white-matter struc-
tures compared to age-matched controls, which we believe
reflects the state of chronic pathological activation. Given that
integrity of white matter and neuron-glia interaction are
essential for learning and memory processes,41 changes
identified in Tgaq*44 mice may reflect or be responsible for
identified cognitive impairment. Our further studies of cortical
implications of BBB dysfunction and brain endothelium
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Figure 8. Lack of ex vivo platelet-dependent prothrombotic state in early stage of heart failure
development in 10-month-old Tgaq*44 as compared to FVB mice. Comparison of platelet count and platelet
thrombus formation process in whole blood between FVB (n=8) and Tgaq*44 (n=8) mice at 10 months of
age employing PL-microchips coated with collagen and T-TAS. A, Platelet count (9103/mm3); (B) T10
(seconds); (C) OT (seconds); and (D) PL12-AUC10. Data distribution is presented as boxplots (median, Q1,
Q3, interquartile range and outliers). OT indicates occlusion time; PL12-AUC10, total thrombogenicity; Tg,
Tgaq*44; T10, time to onset of thrombus formation; T-TAS, Total Thrombus-formation Analysis System
(Fujimori Kogyo Co Ltd, Tokyo, Japan).
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inflammation revealed increased b-amyloid1-42 accumulation
in piriform cortex, increased cortical oxidative stress, and
impairment in NO-dependent cortical arteriole blood flow
regulation. It is known that endothelial dysfunction causes
impairment in neurovascular coupling, partly mediated by
oxidative stress and endothelial NO production impairment.2
Furthermore, decreased NO production was linked to
increased expression of amyloid precursor protein and b-site
amyloid precursor protein–cleaving enzyme 1, which further
increases secretion and brain deposition of b-amyloid.58 In
our model, b-amyloid1-42 was found to be increased in
piriform cortex, the region of the highest amyloid plaque
concentration in the Alzheimer disease model.59
One of the study limitations is that it is based on an artificial
model in which cognitive impairment arises from a single
pathology driven by the cardiomyocyte-specific activation of
the Gaq pathway, whereas clinically, cognitive impairment is a
multifactorial disease. We believe that this limitation is also a
strength of our work because it gave a unique opportunity to
characterize the role of a single risk factor such as HF in
complex pathomechanisms of VCI development, exclusively at
the relatively early stages of HF development in this
model.23,25–31 Another study limitation is the sensitivity of
the CBF assay, on the basis of which we excluded brain
hypoperfusion as a VCI pathomechanism. Magnetic reso-
nance–based CBF assessment did not detect a difference
between Tgaq*44 and FVB mice, but we cannot exclude the
presence of minor regional and functional CBF impairment due
to subtle alterations in the NO-dependent function evidenced
in the isolated cerebral arterioles in ex vivo studies. A
significant reduction in CBF is present in the majority of
vascular and neurodegenerative diseases linked to cognitive
impairment; in advanced HF, CBF was reduced by 30%, and in
Alzheimer disease by 20%,60,61 whereas in experimental
models mimicking hypoperfusion-based VCI (ie, bilateral
common carotid artery stenosis, transverse carotid constric-
tion), CBF reduction reaches 70%.19,20 Therefore, the identified
4% reduction in cortical CBF (based on mean CBF value) in
Tgaq*44 compared to FVB mice, if it proved significant in
larger experimental groups, would still play a marginal role as a
contributor to VCI development in this model. Yet another
study limitation is the possible involvement of other mecha-
nisms of VCI, not studied here, as well as the descriptive
nature of our findings, suggestive of a role of platelets in
disease pathomechanism. Nevertheless, our conclusions are
supported by the time sequence in which VCI pathology
occurs. It begins with platelet hyperresponsiveness in
Tgaq*44 mice at the age of 3 months, at which time the
cardiac function is fully preserved but cardiac inflammation
and fibrosis ensue; this is followed by BBB impairment, brain
pathology, and impaired cognition in Tgaq*44 mice at the age
of 6 months, at which age early-stage diastolic but not systolic
cardiac dysfunction is present; and finally, VCI changes
develop further at the age of 10 months, at which stage both
diastolic and systolic cardiac dysfunctions are present, and
brain endothelium inflammation is further potentiated, but still
this stage does not represent end-stage HF as it occurs
later.29,30,33 Moreover, Tgaq*44 mice at 3 months first show
no changes in BBB permeability and, second, have cognitive
function comparable to wild-type mice at 3, 6, and 10 months.
In contrast, at later time points (6 and 10 months), Tgaq*44
mice show significant and mostly progressive functional and
structural deterioration in comparison to wild-type mice.
Conclusions
In conclusion, we report, to our knowledge for the first time,
that VCI develops in the early stage of experimental HF in
Tgaq*44 mice independently of deterioration of systolic
cardiac function and brain hypoperfusion. Development of
cognitive impairment is preceded by platelet hyperactivity,
which we believe could contribute to dysfunction of BBB, that
is associated with brain endothelium inflammatory activation,
and impairment of NO-dependent regulation of arteriolar brain
microcirculation, oxidative stress, and b-amyloid cortical
accumulation.
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Data S1. 
 
Supplemental Methods 
 
Immunohistochemistry results analyses 
 
Immunohistochemistry results analyses 
 
Raw images acquired with confocal microscopy were analyzed with ImageJ software. Scripts 
presented below demonstrate commands used for each of the analysis.  
 
1. IBA-1 (microglia) immunoreactivity in prefrontal cortex was assessed according to listed ImageJ 
macro: 
 
run("Subtract Background...", "rolling=20"); 
setAutoThreshold("Default dark"); 
//run("Threshold..."); 
call("ij.plugin.frame.ThresholdAdjuster.setMode", "B&W"); 
setAutoThreshold("Huang dark"); 
setThreshold(55, 255); 
run("Convert to Mask"); 
run("Gaussian Blur...", "sigma=1"); 
setOption("BlackBackground", false); 
run("Make Binary"); 
run("Analyze Particles...", "size=55-1500 circularity=0.05-1.00 show=[Overlay Masks] summarize"); 
 
2. GFAP (astrocyte) immunoreactivity in anterior commissure (ROI) was assessed according to listed 
ImageJ macro in respective ROI: 
 
run("Subtract Background...", "rolling=25"); 
run("Auto Local Threshold", "method=Phansalkar radius=25 parameter_1=0 parameter_2=0"); 
run("Options...", "iterations=2 count=6 do=Close"); 
run("Analyze Particles...", "size=30-Infinity show=[Overlay Masks] summarize"); 
run("Analyze Particles...", "size=30-Infinity summarize"); 
 
3. GFAP (astrocyte) immunoreactivity in corpus callosum (ROI) and cingulum (ROI) was assessed 
according to listed ImageJ macro: 
 
run("Subtract Background...", "rolling=10"); 
run("Auto Local Threshold", "method=Phansalkar radius=25 parameter_1=0 parameter_2=0"); 
run("Options...", "iterations=2 count=6 do=Close"); 
run("Analyze Particles...", "size=50-Infinity summarize"); 
 
4. Anterior commissure (ROI) texture was assessed according to listed ImageJ macro: 
 
run("Quantile Based Normalization", "number=1 quantiles=256 replace=mean rescale"); 
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makeRectangle(484, 528, 228, 236); 
run("GLCM Texture", "enter=2 select=[0 degrees] angular contrast correlation inverse entropy"); 
 
5. GFAP (astrocyte) immunoreactivity in dentate gyrus (ROI) was assessed according to listed ImageJ 
macro: 
 
run("Subtract Background...", "rolling=10"); 
run("Auto Local Threshold", "method=Phansalkar radius=25 parameter_1=0 parameter_2=0"); 
run("Options...", "iterations=2 count=6 do=Close"); 
run("Analyze Particles...", "size=30-Infinity summarize"); 
 
6. GFAP (astrocyte) immunoreactivity in lateral ventricle wall (ROI) was assessed according to listed 
ImageJ macro: 
 
run("Subtract Background...", "rolling=25"); 
run("Auto Local Threshold", "method=Phansalkar radius=25 parameter_1=0 parameter_2=0"); 
run("Analyze Particles...", "size=30-Infinity summarize"); 
 
7. IBA-1 (microglia) immunoreactivity in anterior commissure (ROI) was assessed according to listed 
ImageJ macro: 
 
run("Subtract Background...", "rolling=20"); 
setAutoThreshold("Default dark"); 
//run("Threshold..."); 
call("ij.plugin.frame.ThresholdAdjuster.setMode", "B&W"); 
setAutoThreshold("Huang dark"); 
setThreshold(55, 255); 
run("Convert to Mask"); 
run("Gaussian Blur...", "sigma=2"); 
setOption("BlackBackground", false); 
run("Make Binary"); 
run("Analyze Particles...", "size=55-1500circularity=0.05-1.00 show=Masks summarize"); 
 
8. IBA-1 (microglia) immunoreactivity in corpus callosum (ROI) was assessed according to listed 
ImageJ macro: 
 
run("Subtract Background...", "rolling=20"); 
setAutoThreshold("Default dark"); 
//run("Threshold..."); 
call("ij.plugin.frame.ThresholdAdjuster.setMode", "B&W"); 
setAutoThreshold("Huang dark"); 
setThreshold(40, 255); 
run("Convert to Mask"); 
run("Gaussian Blur...", "sigma=1"); 
setOption("BlackBackground", false); 
run("Make Binary"); 
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run("Analyze Particles...", "size=55-Infinity summarize"); 
 
9. IBA-1 (microglia) immunoreactivity in dentate gyrus (ROI) was assessed according to listed ImageJ 
macro: 
 
run("Subtract Background...", "rolling=20"); 
setAutoThreshold("Default dark"); 
//run("Threshold..."); 
call("ij.plugin.frame.ThresholdAdjuster.setMode", "B&W"); 
setAutoThreshold("Huang dark"); 
setThreshold(40, 255); 
run("Convert to Mask"); 
run("Gaussian Blur...", "sigma=1"); 
setOption("BlackBackground", false); 
run("Make Binary"); 
run("Analyze Particles...", "size=50-Infinity summarize"); 
 
10. MBP (myelin basic protein) in corpus callosum (ROI) and cingulum (ROI) was assessed according to 
listed ImageJ macro: 
 
run("Quantile Based Normalization", "add=[files location] choose=[output folder] number=1 
quantiles=256 replace=mean rescale"); 
//run("Threshold..."); 
call("ij.plugin.frame.ThresholdAdjuster.setMode", "B&W"); 
setAutoThreshold("Huang dark"); 
setThreshold(49, 255); 
//setThreshold(49, 255); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
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Table S1. Characteristics of Ab used for immunohistochemistry and flow cytometry.  
 
Ab-I company, cat.no, 
host, stock concentr. 
working 
concentr. 
Ab-II, Cat.no company working 
concentr. 
Anti-BMP Abcam, ab40390 
rabbit,1mg/ml 
1:1.000 Cy3, 711-166-
152, 
donkey anti-
rabbit 
Jackson 
Immuno 
Research 
1:400 
Anti-Iba-1 Abcam, ab5076, 
goat, 0.5mg/ml 
1:500 488 Dylight,705-
486-147, 
donkey anti-goat 
Jackson 
Immuno 
Research 
1:400 
Anti-GFAP Abcam, ab4674, 
chicken,33mg/ml 
1:800 647 Alexa Fluor, 
703-606-155, 
donkey anti-
chicken 
Jackson 
Immuno 
Research 
1:400 
Hoechst 
(33342 
10mg/ml 
Invitrogen, H3570 1:500 405 Jackson 
Immuno 
Research 
1:200 
E-selectin BD Pharmingen, 
550290, rat, 125 µg/ml 
1:50 Cy3, 711-166-
152, 
donkey anti-
rabbit 
Jackson 
Immuno 
Research 
1:800 
aBeta amyloid 
1-42 
Millipore, AB5078P, 
rabbit, 50µg/vial 
1:50 Cy3, 711-166-
152, 
donkey anti-
rabbit 
Jackson 
Immuno 
Research 
1:800 
8OH-dG JAICA, MOG-020P, 
mouse, 20µg/vial 
1:10    
FITC-
CD41/CD61 
Emfret, M025-1, rat, 
N/A 
1µl/assay    
PE-CD41/CD61 
active form 
Emfret, M130-2, rat, 
N/A 
1µl/assay    
PE-CD62p P-
selectin 
Emfret, M023-2, rat, 
N/A 
1µl/assay    
Normal donkey 
serum (NDS) 
Jackson Immuno 
Research, 017-000-121 
    
Vectashield Vector, H-1000     
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Table S2. Statistical difference (p-values) in microglia (IBA-1), astroglia (GFAP) and myelin (MBP) 
specific protein immunoreactivity in selected brain regions between Tg and FVB mice at 6 and 10 months 
of age. 
 
 
 Prefrontal 
Cortex 
Dentate 
Gyrus 
Anterior 
Commissure 
Corpus 
Callosum 
Cingulum Lateral 
Ventricle 
IBA-1 immunoreactivity - mean (SD) 
FVB vs Tg 
at 6 
months 0.04733 0.5905 0.0006543 0.04762‡ 0.3926 N/A 
FVB vs Tg 
at 10 
months 0.1955 0.4856 0.008211 0.006971 0.3521 N/A 
Tg 6 vs 10 
months 0.1497 0.2791 0.02133 0.1499 0.8645 N/A 
FVB 6 vs 
10 months 0.3662 0.8471 0.8184 0.4466 0.1856 N/A 
GFAP immunoreactivity - mean (SD) 
FVB vs Tg 
at 6 
months N/A 0.3593 0.005974 0.07046 0.1028 0.049238 
FVB vs Tg 
at 10 
months N/A 0.306 0.7361 0.8661 0.7458 0.09006 
Tg 6 vs 10 
months N/A 0.5749 0.3609 0.7257 0.4373 0.008432 
FVB 6 vs 
10 months N/A 0.2008 0.0223 0.08222 0.1868 0.4613 
MBP immunoreactivity - mean (SD) 
FVB vs Tg 
at 6 
months N/A N/A 0.001237 0.5319 0.009524‡ N/A 
FVB vs Tg 
at 10 
months N/A N/A 0.01783 0.21 0.1919 N/A 
Tg 6 vs 10 
months N/A N/A  0.1017 0.04429 N/A 
FVB 6 vs 
10 months N/A N/A  0.5739 0.2286‡ N/A 
P values were assessed with t test except for “‡” groups with non-normal data distribution where 
Kolmogorov-Smirnov test was used. 
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Figure S1. ROI selection based on DAPI stain.  
 
 
 
 
a) ROI for texture measurement on anterior commissure; b) ROI for dentate gyrus; c) ROI for corpus 
callosum; d) ROI for cingulum; e) ROI for lateral ventricle wall 
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Figure S2. E-selectin analysis protocol. 
 
 
 
Eight-bit image was transformed to red hot lookup table, after excluding high and low fluorescence 
values, mean image fluorescence was measured, vessel wall was marked with 10-pixel width line and 
mean fluorescence for wall was measured, finally wall fluorescence was subtracted from image mean 
fluorescence to obtain normalized E-selectin vessel wall immunoreactivity. 
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Figure S3. ROI for cortex, hippocampus and thalamus for in vivo CBF imaging based on representative 
sample. 
 
 
 
 
 
a) perfusion map of mice head acquired using FAIR-RARE; b) anatomical images acquired using RAREst 
sequence; c) selection of ROI for cortex, hippocampus and thalamus; d) overlay of identified ROI on 
perfusion map 
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Figure S4. Platelets gating strategy based on representative sample. 
 
 
 
 
a) identification of platelets based on FITC-GpIIbIIIa expression and forward scatter (FSC) event size; b) 
singlet platelets were selected based on events height (FSC-H) and width (FSC-W); c) active form of 
GpIIbIIIa was gated from singlets population based on FMO staining; d) P-selectin was gated from 
singlets population based on FMO staining 
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Figure S5. Development of BBB permeability impairment in early stages of heart failure.  
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Plots represent brain structures (hippocampus, cerebellum, pons) and lungs permeability at all time points 
(3, 6 and 10 months) for all studied permeability markers (NaF, Evans Blue –fluorescence and Evans Blue 
– absorbance); data distribution is presented as boxplots (median, Q1, Q3, interquartile range and 
outliers); f- fluorescence, a- absorbance, p-value * <0.05, **<0.005; (a) – based on absorbance; (f)- based 
on fluorescence 
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Figure S6. High potassium induced contraction and secondary dilation before and after L-NAME in FVB 
(a+b) and Tgαq*44 mice (c+d). 
 
 
 
 
Data distribution is presented as mean and SD. 
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